References
- Apperley JF. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1018–1029.
- Chomel JC, Sorel N, Bonnet ML, et al. Extensive analysis oh the T315I substitution and detection of additional ABL mutations in progenitors and primitive stem cells compartment in a patient with tyrosine kinase inhibitor-resistant chronic myeloid leukemia. Leuk Lymphoma 2010;51:2103–2111.
- Chu S, Xu H, Shah NP, et al. Detection of BCR-ABL kinase mutations in CD34 + cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005;105:2093–2098.
- Soverini S, Iacobucci I, Baccarani M, et al. Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. Haematologica 2007;92:437–439.
- Quintas-Cardama A, Cortes J. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res 2008;14:4392–4399.
- Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia:an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041–6051.
- Polakova KM, Polivkova V, Rulcova J, et al. Constant BCR-ABL transcript level ‡0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis. Exp Hematol 2010;38:20–26.
- Hanfstein B, Müller MC, Kreil S, et al. Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy. Haematologica 2011;96:360–366.
- Pelz-Ackermann O, Cross M, Pfeifer H, et al. Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR. Leukemia 2008;22:2288–2291.
- Kohlmann A, Martinelli G, Hofmann W-K, et al. The Interlaboratory Robustness of Next-Generation Sequencing (IRON) study phase II: deep-sequencing analyses of hematological malignancies performed by an international network involving 26 laboratories. Blood 2012;120(Suppl.): Abstract 1399.
- Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002;100:1014–1018.
- Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients:correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005;106:2128–2137.
- Iqbal Z, Aleem A, Iqbal M, et al. Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34 + cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era. PLoS One 2013;8:e55717.
- Leder K, Foo J, Skaggs B, et al. Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. PLoS One 2011;6:e27682.
- Bolton-Gillespie E, Schemionek M, Klein HU, et al. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood 2013;121:4175–4183.